利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.019 秒)

    Diacylglycerol O-acyltransferase 2α (DGAT2α)
    1.
    发明授权
    Diacylglycerol O-acyltransferase 2α (DGAT2α) 有权
    二酰基甘油O-酰基转移酶2α（DGAT2α）

    公开(公告)号：US07862819B2

    公开(公告)日：2011-01-04

    申请号：US10446441

    申请日：2003-05-27

    申请人： Sylvaine Cases ,  Robert V. Farese ,  Scot J. Stone ,  Ping Zhou

    发明人： Sylvaine Cases ,  Robert V. Farese ,  Scot J. Stone ,  Ping Zhou

    IPC分类号： A61K39/395 ,  C12N9/10 ,  C12N15/09

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  A61K38/00 ,  A61K2039/505 ,  C12Y203/0102 ,  C12Y203/01022

    摘要： Nucleic acid compositions encoding mammalian DGAT2α polypeptide products with diglyceride acyltransferase activity, as well as the mammalian DGAT2α polypeptide products encoded thereby and methods for producing the same, are provided. The subject DGAT2α polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶活性的哺乳动物DGAT2α多肽产物的核酸组合物，以及由此编码的哺乳动物DGAT2α多肽产物及其制备方法。 主题DGAT2α多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用，以及治疗疗法和三酰基甘油的生产。

    Mono- and diacylglycerol acyltransferases and methods of use thereof
    2.
    发明授权
    Mono- and diacylglycerol acyltransferases and methods of use thereof 失效
    单和二酰基甘油酰基转移酶及其使用方法

    公开(公告)号：US07045326B2

    公开(公告)日：2006-05-16

    申请号：US10046924

    申请日：2002-01-14

    申请人： Sylvaine Cases ,  Scot J. Stone ,  Ping Zhou ,  Robert V. Farese, Jr. ,  Chi-Liang Eric Yen

    发明人： Sylvaine Cases ,  Scot J. Stone ,  Ping Zhou ,  Robert V. Farese, Jr. ,  Chi-Liang Eric Yen

    IPC分类号： C12N9/10 ,  C07H21/04

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  A61K38/00 ,  A61K2039/505 ,  C12Y203/0102 ,  C12Y203/01022

    摘要： Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase and/or monoacylglycerol acyltransferase activity, as well as the polypeptide products encoded thereby, i.e., mammalian DGAT2α and MGAT1 polypeptide products, and methods for producing the same, are provided. Also provided are: methods and compositions for modulating DGAT2α and MGAT1 activity; DGAT2α and MGAT1 transgenic cells, animals and plants, as well as methods for their preparation; and methods for making diglyceride, diglyceride compositions, triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry applications.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶和/或单酰基甘油酰基转移酶活性的多肽产物的核酸组合物，以及由此编码的多肽产物，即哺乳动物DGAT2α和MGAT1多肽产物及其制备方法。 还提供了：用于调节DGAT2alpha和MGAT1活性的方法和组合物; DGAT2alpha和MGAT1转基因细胞，动物和植物，以及它们的制备方法; 以及制备甘油二酯，甘油二酯组合物，甘油三酯和甘油三酯组合物的方法以及通过这些方法制备的组合物。 主题方法和组合物可用于各种不同的应用，包括研究，医学，农业和工业应用。

    Diacylglycerol o-acyltransferase
    3.
    发明授权
    Diacylglycerol o-acyltransferase 失效
    二酰基甘油O-酰基转移酶

    公开(公告)号：US06344548B1

    公开(公告)日：2002-02-05

    申请号：US09103754

    申请日：1998-06-24

    申请人： Robert V. Farese, Jr. ,  Sylvaine Cases ,  Steven Smith ,  Sandra K. Erickson

    发明人： Robert V. Farese, Jr. ,  Sylvaine Cases ,  Steven Smith ,  Sandra K. Erickson

    IPC分类号： C07H2104

    CPC分类号： C12N9/1029 ,  A61K38/00 ,  C12N15/8247 ,  C12P7/6463

    摘要： Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase activity, as well as the polypeptide products encoded thereby and methods for producing the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶活性的多肽产物的核酸组合物，以及由此编码的多肽产物及其生产方法。 主题多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用，以及治疗疗法和三酰基甘油的生产。

    Methods of modulating lipid concentrations in eukaryotic cells
    4.
    发明授权
    Methods of modulating lipid concentrations in eukaryotic cells 有权
    调节真核细胞中脂质浓度的方法

    公开(公告)号：US08435790B2

    公开(公告)日：2013-05-07

    申请号：US12508853

    申请日：2009-07-24

    申请人： Robert V. Farese, Jr. ,  Yi Guo ,  Tobias C. Walther ,  Peter Walter

    发明人： Robert V. Farese, Jr. ,  Yi Guo ,  Tobias C. Walther ,  Peter Walter

    IPC分类号： C12N15/01

    CPC分类号： C12P7/649 ,  C12P7/6409 ,  C12P7/6436 ,  C12P7/6463 ,  Y02E50/13

    摘要： The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage.

    摘要翻译： 本发明基于一组参与脂滴形成和调节的基因的发现。 因此，本发明提供通过减少或增加这些基因之一的表达来增加或减少真核细胞中的脂质浓度的方法。 增加的脂质浓度可能是有用的，例如生物燃料的产生。 降低的脂质浓度可用于治疗以过量脂质储存为特征的疾病。 此外，本发明提供鉴定以过量脂质储存为特征的疾病的标志物的方法。

    Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity
    5.
    发明授权
    Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity 有权
    遗传修饰的小鼠缺乏二酰基甘油酰基转移酶-1（DGAT-1）活性

    公开(公告)号：US07745691B2

    公开(公告)日：2010-06-29

    申请号：US11609810

    申请日：2006-12-12

    申请人： Robert V. Farese, Jr. ,  Hubert C. Chen ,  Steven J. Smith ,  Sylvaine Cases ,  Sandra K. Erickson

    发明人： Robert V. Farese, Jr. ,  Hubert C. Chen ,  Steven J. Smith ,  Sylvaine Cases ,  Sandra K. Erickson

    IPC分类号： A01K67/027 ,  A01K67/00 ,  G01N33/00

    CPC分类号： G01N33/5088 ,  A61K38/00 ,  C12N9/1029 ,  C12N15/8247 ,  C12P7/64 ,  G01N2800/042

    摘要： Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.

    摘要翻译： 提供了调节宿主中碳水化合物代谢的方法和组合物。 在主题方法中，二酰基甘油酰基转移酶（DGAT）活性（特别是DGAT1活性）被调节，例如降低或增强，以达到所需的胰岛素和/或瘦素敏感性，从而调节碳水化合物代谢，例如增加或降低血糖水平， 葡萄糖摄入细胞并同化成糖原。 还提供了用于实践本发明方法的药物组合物。 主题方法和组合物可用于各种应用，包括治疗与异常碳水化合物代谢相关的疾病如肥胖或糖尿病的宿主。

    Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors
    8.
    发明授权
    Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors 有权
    用蛋白激酶C抑制剂治疗肥胖症，代谢综合征和糖尿病

    公开(公告)号：US08580769B2

    公开(公告)日：2013-11-12

    申请号：US13417075

    申请日：2012-03-09

    申请人： Robert V. Farese

    发明人： Robert V. Farese

    IPC分类号： A61K31/675 ,  A61K31/28 ,  A61K31/4164 ,  A61K31/155

    CPC分类号： A61K31/4164 ,  A61K31/155 ,  A61K31/29 ,  A61K31/66 ,  A61K31/7135 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-ι, thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifically inhibits hepatic PKC-ι includes a thio-gold compound (such as aurothiomalate, aurothioglucose, and auranofin) or a derivative thereof, or a pharmaceutically acceptable salt thereof. In other embodiments, the compound that specifically inhibits hepatic PKC-ι includes 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-[1R-(1α,2β,3β,4α)] (ICAPP) or a derivative thereof, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本文公开了治疗肥胖，代谢综合征，糖尿病或这些病症的组合的方法。 所述方法包括选择患有肥胖，代谢综合征或糖尿病的受试者，并向受试者施用治疗有效量的包含特异性抑制肝蛋白激酶C（PKC）的化合物的组合物，从而治疗肥胖，代谢综合征， 或糖尿病。 在一些实施方案中，特异性抑制肝脏PKC-iota的化合物包括硫代金化合物（例如亚硫辛酸，亚硫代葡萄糖和泛酰诺芬）或其衍生物或其药学上可接受的盐。 在其它实施方案中，特异性抑制肝脏PKC-iota的化合物包括1H-咪唑-4-甲酰胺，5-氨基-1- [2,3-二羟基-4 - [（膦酰氧基）甲基]环戊基] - [1R-（ 1α，2beta，3beta，4alpha）]（ICAPP）或其衍生物或其药学上可接受的盐。